ISTOCK, BUBAONE
We obtained approval of Clinical Trial Applications (CTA) in multiple countries for both β-thalassemia and sickle cell disease ((SCD)) and we continue to work closely with various clinical sites to initiate these trials. In parallel, we are working diligently with the FDA and have a clear path to resolve the current clinical hold of the Investigational New Drug application ((IND)) in the U.S. for SCD. - Samarth Kulkarni, Ph.D. CEO
My primary interest going into this earnings report was focused on three issues:
- Would there be any meaningful change in the cash runway?